These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8101675)

  • 1. Antihistamines and the heart.
    Marquardt D
    West J Med; 1993 Jun; 158(6):613-4. PubMed ID: 8101675
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug interactions associated with terfenadine and related nonsedating antihistamines.
    Zechnich AD; Haxby DG
    West J Med; 1996 Jan; 164(1):68-9. PubMed ID: 8779212
    [No Abstract]   [Full Text] [Related]  

  • 3. [Risk of drug interactions. Combinations of drugs associated with ventricular arrhythmias].
    Viramontes-Madrid JL; Jerjes-Sánchez C; Pelaez-Ballestas I; Aguilar-Chiu A; Hernández-Garduño AG
    Rev Invest Clin; 2002; 54(3):192-7. PubMed ID: 12183887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)-induced ventricular arrhythmias.
    Wynn RL
    Gen Dent; 1993; 41(1):27-9. PubMed ID: 7489857
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.
    Hey JA; del Prado M; Sherwood J; Kreutner W; Egan RW
    Arzneimittelforschung; 1996 Feb; 46(2):153-8. PubMed ID: 8720304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug side effects and their prevention].
    Hautarzt; 1997 Aug; 48(8 Suppl):3-4. PubMed ID: 9378645
    [No Abstract]   [Full Text] [Related]  

  • 7. Terfenadine therapy: can we justify the risks?
    Rangno R
    CMAJ; 1997 Jul; 157(1):37-8. PubMed ID: 9220940
    [No Abstract]   [Full Text] [Related]  

  • 8. Dangers of non-sedating antihistamines.
    Clark S
    Lancet; 1997 May; 349(9061):1268. PubMed ID: 9142059
    [No Abstract]   [Full Text] [Related]  

  • 9. [The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?].
    Pelov R; Tankova L; Krushkov I
    Vutr Boles; 1999; 31(2-3):5-9. PubMed ID: 10847134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation antihistamines: the risk of ventricular arrhythmias.
    DuBuske LM
    Clin Ther; 1999 Feb; 21(2):281-95. PubMed ID: 10211532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terfenadine and SSRIs.
    Tafler G
    CMAJ; 1997 Oct; 157(8):1019. PubMed ID: 9347771
    [No Abstract]   [Full Text] [Related]  

  • 12. Dangers of non-sedating antihistamines.
    Himmel MH; Honig PK; Worobec AS
    Lancet; 1997 Jul; 350(9070):69; author reply 69-70. PubMed ID: 9217741
    [No Abstract]   [Full Text] [Related]  

  • 13. QT lengthening and life-threatening arrhythmias associated with fexofenadine.
    Craig-McFeely PM; Freemantle SL; Pearce GL; Shakir SA
    Br J Gen Pract; 2000 Feb; 50(451):148. PubMed ID: 10750216
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged QTc time and ventricular arrhythmia with fexofenadine.
    Kashyap AS; Kashyap S
    Am J Cardiol; 1999 Nov; 84(10):1278-9. PubMed ID: 10569349
    [No Abstract]   [Full Text] [Related]  

  • 15. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization.
    Hanrahan JP; Choo PW; Carlson W; Greineder D; Faich GA; Platt R
    Ann Epidemiol; 1995 May; 5(3):201-9. PubMed ID: 7606309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing face of antihistamines and cardiac adverse drug reactions: a clinical perspective.
    Shaikh WA
    J Indian Med Assoc; 2000 Jul; 98(7):397-9. PubMed ID: 11143865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Special drug communication teleconference. August 7, 1992.
    Ear Nose Throat J; 1992 Sep; 71(9):383-4, 387-90. PubMed ID: 1425376
    [No Abstract]   [Full Text] [Related]  

  • 18. Causality assessment of adverse drug effects: when is rechallenge ethically acceptable?
    Po AL; Kendall MJ
    Lancet; 1999 Aug; 354(9179):683. PubMed ID: 10466699
    [No Abstract]   [Full Text] [Related]  

  • 19. Seldane warnings.
    Vazquez E; Whitfield L
    Posit Aware; 1997; 8(6):12. PubMed ID: 11364851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?
    Flockhart DA
    J Clin Psychopharmacol; 1996 Apr; 16(2):101-3. PubMed ID: 8690824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.